Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.54 |
| ▸ | PIM1 | P11309 | 5/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.52 |
| ▸ | LTK | P29376 | 1/20 | 0.51 |
| ▸ | MST1R | Q04912 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.50 |
| ▸ | STK3 | Q13188 | 3/20 | 0.50 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.50 |
| ▸ | TAOK1 | Q7L7X3 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30331758 | 0.84 | PARP10 (0.69) | KDRCLK4PIM1ROCK1DYRK1A | |
| SCHEMBL19608227 | 0.83 | PIK3CD (0.64) | KDRCLK4PIM1ROCK1DYRK1A | |
| SCHEMBL28223904 | 0.83 | PIK3CD (0.64) | KDRCLK4PIM1ROCK1DYRK1A | |
| SCHEMBL28860691 | 0.82 | KDR (0.54) | KDRCLK4PIM1ROCK1DYRK1A | |
| SCHEMBL29845432 | 0.81 | CLK4 (0.57) | KDRCLK4PIM1ROCK1DYRK1A | |
| SCHEMBL30775282 | 0.80 | KDR (0.58) | KDRCLK4PIM1ROCK1DYRK1A | |
| SCHEMBL30543353 | 0.79 | KDR (0.62) | KDRCLK4PIM1ROCK1DYRK1A | |
| SCHEMBL30543378 | 0.79 | GRM2 (0.44) | KDRCLK4PIM1ROCK1DYRK1A | |
| SCHEMBL29222581 | 0.79 | GRM2 (0.44) | KDRCLK4PIM1ROCK1DYRK1A | |
| SCHEMBL30775285 | 0.79 | KDR (0.57) | KDRCLK4PIM1ROCK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| EP-2640698-A1 | NAMPT AND ROCK INHIBITORS | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012067965-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2012061602-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | WO | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110275630-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2011-11-10 | — | — | US | disclosed |
| US-20100076051-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20060287370-A1 | Isoindolinone kinase inhibitors | CURTIN MICHAEL L | 2006-12-21 | — | — | US | disclosed |
| US-7129260-B2 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| EP-1633710-A1 | ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS | Abbott Laboratories (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| WO-2004108672-A1 | ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | KDR 2131/4885CLK4 3582/4885PIM1 2350/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | KDR 2828/4885CLK4 4430/4885PIM1 4079/4885 |
| US-20060287370-A1 | Isoindolinone kinase inhibitors | ABL1, LCK, MAP3K7 | KDR 527/4885CLK4 604/4885PIM1 286/4885 |
| US-20160031880-A1 | Nampt and Rock Inhibitors | NAMPT, NNMT, NME2 | KDR 2828/4885CLK4 4430/4885PIM1 4079/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | KDR 20/4885CLK4 1236/4885PIM1 201/4885 |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABL1, LCK, MAP3K7 | KDR 527/4885CLK4 604/4885PIM1 286/4885 |
| US-20100076051-A1 | ISOINDOLINONE KINASE INHIBITORS | ABL1, LCK, MAP3K7 | KDR 527/4885CLK4 604/4885PIM1 286/4885 |
| US-20110275630-A1 | ISOINDOLINONE KINASE INHIBITORS | MAP3K7, MAP3K5, MAP3K20 | KDR 909/4885CLK4 483/4885PIM1 331/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | KDR 41/4885CLK4 1222/4885PIM1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.